Arthritis drug could let coeliac patients eat gluten


Thursday, 30 July, 2020

Arthritis drug could let coeliac patients eat gluten

A treatment for rheumatoid arthritis and bowel disease could allow people with coeliac disease to eat gluten without consequences.

The discovery was made at University Hospitals Leuven in Belgium, where a patient treated with tofacitinib for alopecia surprisingly found that the drug caused his coeliac disease to go into remission, despite eating a gluten-containing diet.

A case report published in Annals of Internal Medicine describes that, after achieving some remission following a gluten-free diet, the patient resumed eating gluten and had symptoms on and off, still suffering from alopecia. After discussing the risks and benefits, the patient decided on watchful waiting. He did not return to a gluten-free diet, but started off-label use of tofacitinib for alopecia.

Follow-up investigations unexpectedly showed complete histologic and serologic remission of coeliac disease while he was still on a gluten-containing diet. The patient continued tofacitinib use, with regular blood tests showing normal complete blood count, lipid levels and creatine kinase levels.

Coeliac disease, or gluten intolerance, requires a lifelong gluten-free diet, as no other non-dietary treatments have established efficacy. Dietary adherence is crucial for mucosal healing and prevention of long-term complications, but complete avoidance of gluten is difficult for even the most committed patients.

The research team says that while these results are encouraging for those with the disease, the side effects of tofacitinib may limit its use for everyone.

Image credit: ©stock.adobe.com/au/timmary

Related News

$1bn vaccine and antivenom manufacturing facility opens

A $1 billion cell-based influenza vaccine and antivenom manufacturing facility has opened in...

National concussion clinical guidelines now available

The first Australia- and New Zealand-specific guidelines for all forms of concussion — from...

Doctors criticise "risky prescribing agenda"

The AMA and RACGP have expressed disappointment in the Pharmacy Board of Australia's...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd